Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial.
FDA Grants Accelerated Approval to Pfizer’s Braftovi Combination for Metastatic Colorectal Cancer
Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial.